WallStreetZenWallStreetZen

NASDAQ: FENC
Fennec Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for FENC

Based on 2 analysts offering 12 month price targets for Fennec Pharmaceuticals Inc

Min Forecast
$13.00+60.69%
Avg Forecast
$13.50+66.87%
Max Forecast
$14.00+73.05%

Should I buy or sell FENC stock?

Based on 2 analysts offering ratings for Fennec Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Strong Buy" agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their FENC stock forecasts and price targets.

FENC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-21
lockedlocked$00.00+00.00%2025-08-15

1 of 1

Forecast return on equity

Is FENC forecast to generate an efficient return?

Company
N/A
Industry
250.86%
Market
228.7%

Forecast return on assets

Is FENC forecast to generate an efficient return on assets?

Company
N/A
Industry
90.06%

FENC earnings per share forecast

What is FENC's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.13
Avg 2 year Forecast
$0.67
Avg 3 year Forecast
$1.05

FENC revenue forecast

What is FENC's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$45.7M+17.93%
Avg 2 year Forecast
$78.2M+101.62%
Avg 3 year Forecast
$93.5M+140.97%
FENC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

FENC revenue growth forecast

How is FENC forecast to perform vs Biotechnology companies and vs the US market?

Company
35.6%
Industry
97.96%
Market
25.83%
FENC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
FENC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

FENC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
FENC$8.09$13.50+66.87%Buy
VYGR$4.08$16.50+304.41%Buy
PRQR$2.17$4.00+84.33%Strong Buy
HRTX$1.28$3.00+134.38%Buy
ACHV$4.49$15.50+245.60%Buy
View Top Biotech Stocks

Fennec Pharmaceuticals Stock Forecast FAQ

Is Fennec Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: FENC) stock is to Buy FENC stock.

Out of 2 analysts, 0 (0%) are recommending FENC as a Strong Buy, 2 (100%) are recommending FENC as a Buy, 0 (0%) are recommending FENC as a Hold, 0 (0%) are recommending FENC as a Sell, and 0 (0%) are recommending FENC as a Strong Sell.

If you're new to stock investing, here's how to buy Fennec Pharmaceuticals stock.

What is FENC's earnings growth forecast for 2025-2027?

(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.

Fennec Pharmaceuticals's earnings in 2025 is -$6,940,000.On average, 7 Wall Street analysts forecast FENC's earnings for 2025 to be -$3,556,779, with the lowest FENC earnings forecast at -$4,959,809, and the highest FENC earnings forecast at -$2,066,587. On average, 7 Wall Street analysts forecast FENC's earnings for 2026 to be $18,697,691, with the lowest FENC earnings forecast at $13,501,701, and the highest FENC earnings forecast at $27,160,857.

In 2027, FENC is forecast to generate $29,612,644 in earnings, with the lowest earnings forecast at $24,523,498 and the highest earnings forecast at $33,951,071.

What is FENC's revenue growth forecast for 2025-2027?

(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual revenue growth rate of 35.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.83%.

Fennec Pharmaceuticals's revenue in 2025 is $38,790,000.On average, 7 Wall Street analysts forecast FENC's revenue for 2025 to be $1,286,204,343, with the lowest FENC revenue forecast at $1,172,078,134, and the highest FENC revenue forecast at $1,377,977,672. On average, 7 Wall Street analysts forecast FENC's revenue for 2026 to be $2,198,989,079, with the lowest FENC revenue forecast at $1,668,930,619, and the highest FENC revenue forecast at $2,567,516,357.

In 2027, FENC is forecast to generate $2,628,108,123 in revenue, with the lowest revenue forecast at $2,259,299,677 and the highest revenue forecast at $3,142,899,146.

What is FENC's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: FENC) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 90.06%.

What is FENC's Price Target?

According to 2 Wall Street analysts that have issued a 1 year FENC price target, the average FENC price target is $13.50, with the highest FENC stock price forecast at $14.00 and the lowest FENC stock price forecast at $13.00.

On average, Wall Street analysts predict that Fennec Pharmaceuticals's share price could reach $13.50 by Aug 21, 2026. The average Fennec Pharmaceuticals stock price prediction forecasts a potential upside of 66.87% from the current FENC share price of $8.09.

What is FENC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: FENC) Fennec Pharmaceuticals's current Earnings Per Share (EPS) is -$0.25. On average, analysts forecast that FENC's EPS will be -$0.13 for 2025, with the lowest EPS forecast at -$0.18, and the highest EPS forecast at -$0.07. On average, analysts forecast that FENC's EPS will be $0.67 for 2026, with the lowest EPS forecast at $0.48, and the highest EPS forecast at $0.97. In 2027, FENC's EPS is forecast to hit $1.05 (min: $0.87, max: $1.21).

What is FENC's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: FENC) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.